Cyclerion Therapeutics, Inc.CYCNNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank13
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P13
Within normal range
vs 5Y Ago
-1.4x
Contraction
Streak
1 yr
Consecutive growthDecelerating
PeriodValue
2024-35.89%
2023-37.15%
2022-35.70%
2021-28.44%
2020-16.24%
201924.94%
201882.13%
201744.31%
20160.00%